全文获取类型
收费全文 | 1432445篇 |
免费 | 122454篇 |
国内免费 | 4241篇 |
专业分类
耳鼻咽喉 | 23288篇 |
儿科学 | 47827篇 |
妇产科学 | 40371篇 |
基础医学 | 192208篇 |
口腔科学 | 37229篇 |
临床医学 | 134681篇 |
内科学 | 297953篇 |
皮肤病学 | 33902篇 |
神经病学 | 113937篇 |
特种医学 | 56773篇 |
外国民族医学 | 369篇 |
外科学 | 237388篇 |
综合类 | 26880篇 |
现状与发展 | 73篇 |
一般理论 | 324篇 |
预防医学 | 100665篇 |
眼科学 | 32514篇 |
药学 | 99807篇 |
1篇 | |
中国医学 | 2526篇 |
肿瘤学 | 80424篇 |
出版年
2018年 | 18887篇 |
2017年 | 15992篇 |
2016年 | 18076篇 |
2015年 | 19645篇 |
2014年 | 30803篇 |
2013年 | 39433篇 |
2012年 | 39510篇 |
2011年 | 41923篇 |
2010年 | 31290篇 |
2009年 | 33676篇 |
2008年 | 41135篇 |
2007年 | 42569篇 |
2006年 | 45402篇 |
2005年 | 42162篇 |
2004年 | 40027篇 |
2003年 | 37983篇 |
2002年 | 37621篇 |
2001年 | 62101篇 |
2000年 | 62829篇 |
1999年 | 54077篇 |
1998年 | 17828篇 |
1997年 | 16150篇 |
1996年 | 16281篇 |
1995年 | 15373篇 |
1994年 | 13635篇 |
1993年 | 12368篇 |
1992年 | 42444篇 |
1991年 | 41863篇 |
1990年 | 41089篇 |
1989年 | 39979篇 |
1988年 | 37223篇 |
1987年 | 36336篇 |
1986年 | 34706篇 |
1985年 | 32960篇 |
1984年 | 24573篇 |
1983年 | 21414篇 |
1982年 | 12934篇 |
1981年 | 11363篇 |
1979年 | 23028篇 |
1978年 | 16290篇 |
1977年 | 14171篇 |
1976年 | 13243篇 |
1975年 | 14535篇 |
1974年 | 16969篇 |
1973年 | 16360篇 |
1972年 | 15652篇 |
1971年 | 14467篇 |
1970年 | 13506篇 |
1969年 | 12867篇 |
1968年 | 12035篇 |
排序方式: 共有10000条查询结果,搜索用时 10 毫秒
91.
Susan M Domchek Andrea Eisen Kathleen Calzone Jill Stopfer Anne Blackwood Barbara L Weber 《Journal of clinical oncology》2003,21(4):593-601
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families. 相似文献
92.
93.
Andrea R Genazzani Hermann P G Schneider Nick Panay Esme A Nijland 《Gynecological endocrinology》2006,22(7):369-375
OBJECTIVES: To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer. METHODS: Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol. RESULTS: Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media. CONCLUSIONS: This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use. 相似文献
94.
95.
C G Arruda J M Aldrighi L A Bortolotto I N Alecrin J A F Ramires 《Gynecological endocrinology》2006,22(10):557-563
BACKGROUND: Arterial hypertension and postmenopausal reduction of estrogen levels may be involved in modifications of the stiffness of large arteries. OBJECTIVES: To evaluate the pulse-wave velocity (PWV) and indirectly the arterial stiffness in hypertensive postmenopausal women submitted to hormone therapy with estradiol alone or combined with norethisterone acetate. SUBJECTS: Forty-five hypertensive postmenopausal women were double-blindly, randomly assigned to three arms of treatment: placebo (group I); estradiol 2 mg/day (group II); or estradiol 2 mg/day and norethisterone acetate 1 mg/day (group III). METHODS: Arterial stiffness was assessed from PWV measurements of the common carotid and femoral arteries (CF-PWV) and the common carotid and radial arteries (CR-PWV) obtained using the automatic Complior(R) device, taken at baseline and after 12 weeks of treatment. RESULTS: After the 12-week treatment, values of CF-PWV and CR-PWV were not significantly different (p = 0.910 and p = 0.736, respectively) among the groups. Systolic blood pressure showed a positive correlation with CF-PWV in groups II and III (p = 0.02 and p < 0.001, respectively). CONCLUSIONS: PWV and arterial stiffness in postmenopausal hypertensive women did not reduce over a 12-week treatment with estradiol alone compared with the same period of treatment with estradiol combined with norethisterone acetate. 相似文献
96.
97.
G N J Tytgat 《Acta chirurgica. Supplement》2002,(587):77-81
A true comparison of long-term medical and surgical treatment in gastro-oesophageal reflux disease (GORD) is impossible as few studies have been carried out with adequate randomisation of the patients and long-term evaluation of quality of life. In general the control of the reflux symptoms is roughly equal with medical and surgical treatment. However, surgery can cause other symptoms such as dysphagia or non-specific epigastric discomfort or pain in some patients, which reduces the overall efficacy in controlling the symptoms. Based on a cost utility analysis, Heudebert et al. came to the conclusion that medical treatment was their preferred strategy for most patients with severe erosive oesophagitis. 相似文献
98.
99.
100.
Angiotensin Converting Enzyme Inhibitors: Animal Experiments Suggest a New Pharmacological Treatment for Alcohol Abuse in Humans 总被引:1,自引:0,他引:1
G. Spinosa MSc E. Perlanski Dipl Tech. F. H. H. Leenen MD R. B. Stewart MSc L. A. Grupp DSc 《Alcoholism, clinical and experimental research》1988,12(1):65-70
The prevalence of heavy alcohol consumption is a major problem of increasing proportions throughout the world. Although alcohol sensitizing drugs and more recently serotonin uptake inhibitors are drug interventions with some following, their long term beneficial consequences have yet to be demonstrated. In recent years, we have demonstrated that manipulating activity in the renin-angiotensin system will dramatically alter voluntary alcohol consumption in rats. Based on these findings, the present study evaluated the ability of a class of drugs known as the angiotensin converting enzyme inhibitors to reduce voluntary alcohol drinking in laboratory animals. These drugs prevent the conversion of angiotensin I to angiotensin II. They have been licensed for use in Europe and North America and are indicated in the treatment of hypertension. Our experiments showed that both captopril (Capoten, Squibb) and enalapril (Vasotec, Merck Sharpe & Dohme) can reduce alcohol drinking in both normotensive and hypertensive animals regardless of whether the pattern of intake is in a bout or of a less exaggerated nature. Furthermore, this change in alcohol intake can occur without concomitant changes in blood pressure, plasma renin activity, overall fluid balance, or the distribution and metabolism of alcohol. Taken together these findings suggest that the angiotensin converting enzyme inhibitors should be evaluated in a clinical setting for they may prove to be a useful new treatment or treatment adjunct for alcohol abuse in humans. 相似文献